Triethyl citrateCAS# 77-93-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 77-93-0 | SDF | Download SDF |
| PubChem ID | 6506 | Appearance | Powder |
| Formula | C12H20O7 | M.Wt | 276.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | triethyl 2-hydroxypropane-1,2,3-tricarboxylate | ||
| SMILES | CCOC(=O)CC(CC(=O)OCC)(C(=O)OCC)O | ||
| Standard InChIKey | DOOTYTYQINUNNV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H20O7/c1-4-17-9(13)7-12(16,11(15)19-6-3)8-10(14)18-5-2/h16H,4-8H2,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Triethyl citrate Dilution Calculator
Triethyl citrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.6193 mL | 18.0963 mL | 36.1925 mL | 72.3851 mL | 90.4814 mL |
| 5 mM | 0.7239 mL | 3.6193 mL | 7.2385 mL | 14.477 mL | 18.0963 mL |
| 10 mM | 0.3619 mL | 1.8096 mL | 3.6193 mL | 7.2385 mL | 9.0481 mL |
| 50 mM | 0.0724 mL | 0.3619 mL | 0.7239 mL | 1.4477 mL | 1.8096 mL |
| 100 mM | 0.0362 mL | 0.181 mL | 0.3619 mL | 0.7239 mL | 0.9048 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Citric acid
Catalog No.:BCN5374
CAS No.:77-92-9
- Trometamol
Catalog No.:BCC4743
CAS No.:77-86-1
- Tigogenin
Catalog No.:BCN5327
CAS No.:77-60-1
- Tomatidine
Catalog No.:BCN2773
CAS No.:77-59-8
- Cedrol
Catalog No.:BCN8340
CAS No.:77-53-2
- Ursolic acid
Catalog No.:BCN4327
CAS No.:77-52-1
- Chlorthalidone
Catalog No.:BCC4649
CAS No.:77-36-1
- Gibberellins
Catalog No.:BCN2189
CAS No.:77-06-5
- Garcinone C
Catalog No.:BCN4322
CAS No.:76996-27-5
- Euphroside
Catalog No.:BCN6633
CAS No.:76994-07-5
- Notoginsenoside T5
Catalog No.:BCN3727
CAS No.:769932-34-5
- 15-Methoxypinusolidic acid
Catalog No.:BCN4321
CAS No.:769928-72-5
- D-(-)-Quinic acid
Catalog No.:BCN1029
CAS No.:77-95-2
- (+,-)-Octopamine HCl
Catalog No.:BCC4814
CAS No.:770-05-8
- Dehydropachymic acid
Catalog No.:BCN3648
CAS No.:77012-31-8
- Hypocrellin A
Catalog No.:BCN3396
CAS No.:77029-83-5
- Knightinol
Catalog No.:BCN1913
CAS No.:77053-06-6
- Acetylknightinol
Catalog No.:BCN1914
CAS No.:77053-07-7
- Gadobutrol
Catalog No.:BCC4164
CAS No.:770691-21-9
- 6-O-trans-Feruloylcatalpol
Catalog No.:BCN4323
CAS No.:125205-48-3
- 2H-1-Benzopyran-5-ol
Catalog No.:BCN3581
CAS No.:770729-34-5
- MK-801 (Dizocilpine)
Catalog No.:BCC4591
CAS No.:77086-21-6
- (+)-MK 801 Maleate
Catalog No.:BCC4014
CAS No.:77086-22-7
- 1H-Indole-3-carboxylic acid
Catalog No.:BCN4324
CAS No.:771-50-6
Impact of formulation excipients on the thermal, mechanical, and electrokinetic properties of hydroxypropyl methylcellulose acetate succinate (HPMCAS).[Pubmed:29458211]
Int J Pharm. 2018 May 5;542(1-2):132-141.
Hydroxypropyl methylcellulose acetate succinate (HPMCAS) has been widely used in amorphous solid dispersions and as an enteric coating polymer. Under aqueous coating conditions and at elevated coating temperatures, HPMCAS particles tend to aggregate and clog the spray-nozzle, hence interrupting the coating process. This research focused on how plasticizers and surfactants, excipients used for aqueous coating, affect the properties and stability of HPMCAS. This information would be useful in identifying suitable excipients for developing a stable HPMCAS aqueous enteric coating formulation. Triethyl citrate was found to be the most compatible plasticizer with HPMCAS, and displayed suitable thermal and mechanical properties. PEG 4000, the co-plasticizer, provided dispersion stability by yielding a dispersible sediment without aggregation at the elevated processing temperatures. Zeta potential measurements indicated sodium lauryl sulfate (SLS) could be used as a potential stabilizing agent at concentrations above its critical micelle concentration (CMC). This study facilitated the understanding of the HPMCAS aggregation mechanism, in addition to identifying suitable stabilizing agents. These stabilizing excipients could potentially be used to develop a stable aqueous coating formulation that does not exhibit polymer aggregation and nozzle clogging during the coating process.
Dry powder coated osmotic drug delivery system.[Pubmed:28986194]
Eur J Pharm Sci. 2018 Jan 1;111:383-392.
Dry powder coated osmotic drug delivery system (ODDS) were prepared and characterized using an innovative powder coating technology. Coating powder adhesion to the surface of the ODDS core was firstly performed through an electrostatic spray gun, followed by a curing step to allow those electrically deposited particles coalesce and form a continuous, uniform and strong coating film, which is the semipermeable membrane of the ODDS. Triethyl citrate (TEC) was found to be a better liquid plasticizer than PEG 400 both in reducing the glass transition temperature of the coating polymer (cellulose acetate) and in increasing the electrical conductivity of the ODDS cores, both of which led to an enhanced coating powder adhesion and film formation. Results of SEM indicated that the uniformity of the coating film varied significantly with the difference of curing time and temperature. Salbutamol sulfate and ibuprofen were used as the model drugs. Release profiles of both showed that zero-order drug release kinetics was achieved. Release rate of both drugs from powder coated ODDS could be adjusted by changing the coating level but was independent of the agitation speed and of the pH of the release media.
